Dalpiciclib combined with endocrine therapy for patients with HR+/HER2− metastatic breast cancer: a multicenter real-world study
Xuelian Chen, Lin Lin, Guangning He, Guanghui Ren, Jiayi Huang, Liping Chen, Xiaofeng Lan, Xiaofeng Xie, Lin Song, Xue Bai, Caiwen Du · 2026
Read Dalpiciclib combined with endocrine therapy for patients with HR+/HER2− metastatic breast cancer: a multicenter real-world study by Xuelian Chen, Lin Lin, Guangning He, Guanghui Ren, Jiayi Huang, Liping Chen, Xiaofeng Lan, Xiaofeng Xie, Lin Song, Xue Bai, Caiwen Du (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13424527.txt.
Description
Xuelian Chen leads an eleven-author real-world study of dalpiciclib, China's newest CDK4/6 blocker, combined with hormone therapy for metastatic breast cancer that is hormone-receptor positive and HER2 negative. Records came from four centres in South China covering 160 patients treated between January 2022 and March 2025, a broader mix than trial populations.
Median follow-up was just under eighteen months. Across the cohort, the typical time before the cancer progressed was about twenty-one months, and roughly a sixth of patients saw tumours shrink measurably. First-line use did much better, at nearly twenty-seven months, than later-line use at about fourteen months. Even the thirteen patients with brain spread reached a median of about fifteen months. Safety data were collected alongside.
Catalog record
| CREATOR | Xuelian Chen, Lin Lin, Guangning He, Guanghui Ren, Jiayi Huang, Liping Chen, Xiaofeng Lan, Xiaofeng Xie, Lin Song, Xue Bai, Caiwen Du |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |